C. Lin, S. Richards, R. Paver
Introduction: Mohs surgery utilises intra-operative frozen sections to control tumour margins, thus achieving a high clearance rate for non-melanoma skin cancers. It is traditionally reserved for recurrent cancers, those with illdeﬁned clinical margins, or for sites where tissue conservation is of paramount importance.
Method: Retrospective analysis was performed on 500 consecutive Mohs surgery patients who attended the Skin and Cancer foundation in Sydney from May 2013. Basic demographic data, previous treatments, stages and sections required for clearance, tumour types and sizes, and ﬁnal defect sizes were collected from patient ﬁles. Comparisons between primary and recurrent tumours are made, and sub-analysis for recurrent tumours performed according to previous treatments.
Results: To be discussed at the Mohs Meeting. The results may potentially encourage practitioners to consider Mohs surgery as a treatment option earlier on in the patient management pathway.